Core Viewpoint - Harbin Yuheng Pharmaceutical Co., Ltd. has approved the use of idle self-owned funds for entrusted wealth management, allowing up to RMB 390 million to be invested in medium or lower-risk financial products within a year [1][7]. Group 1: Wealth Management Plan - The company and its subsidiaries will utilize idle funds to purchase wealth management products from financial institutions, with a total investment limit of RMB 390 million [1]. - Guangzhou Yudong has already invested RMB 200 million in wealth management products [1]. - The wealth management products include various fixed-income assets such as bank deposits, government bonds, corporate bonds, and other standardized debt instruments [2][4][5]. Group 2: Investment Details - The wealth management products purchased include those managed by Anxin Securities Asset Management Co., Ltd. and Guotou Investment Management, which do not involve stocks, futures, or derivatives [3][4]. - The total amount invested in Anxin's products is RMB 30 million, with specific purchase amounts and interest start dates detailed [2][3]. - The company has also invested RMB 5 million in products from Huaxia Wealth Management, which focuses entirely on fixed-income financial instruments [6][8]. Group 3: Financial Impact - As of May 12, 2025, the total amount of outstanding entrusted wealth management products is RMB 220 million, representing 11.28% of the company's latest audited net assets attributable to shareholders [8]. - The company aims to enhance the efficiency of idle funds and increase cash management returns without affecting daily operational needs [7].